- Vanguard VCLT and Schwab SCHQ: Long-Term Bond ETF Investment Options
- Lumentum Financial Report in Depth: First $1 Billion Quarter Surpasses 50% Gross Margin, Can In-Rack Optics Connect to Growth in 2028?
- Capstone Holding posts investor presentation after filing Q2 10-Q
- Progen 1H FY26 returns to profit of S$285,000; revenue rises to S$6.86 million, up 236.4%
- British Pound: Strong Q2 may give way to flat growth - TD Securities
- Rekor Systems says GoSecure adds patent-pending audio verification technology
- Zcash trades at $480 as CPI data and Ironwood migration sway sentiment
- Capstone Therapeutics restates Q3 2025 weighted-average shares, lifts loss per share to USD 0.34
- Zoomcar updates financial calendar with Q1 results webcast scheduled
- Adagene FY26 H1 net loss widens to US$ 16.4 million; revenue turns to US$ 1.6 million
- NatWest tracker shows UK business activity expands in 10 of 12 regions in July
- Spot palladium has just surpassed the $1,400.00 per ounce mark, last quoted at $1,400.75 per ounce with a daily gain of 2.47%. Nymex palladium futures most active contract is currently quoted at $1,401.50 per ounce, up 2.31% on the day.
- Spot platinum has just broken through the $1,790.00/oz mark, now quoted at $1,790.05/oz, up 2.72% on the day; Nymex platinum futures main contract is now quoted at $1,802.2/oz, up 2.70% on the day.
- NASDAQ TRADE HALT <TBCVU.O> REASON NOT AVAILABLE AT 07:35 AM
- Capstone Therapeutics says prior quarterly EPS figures should no longer be relied upon after share-count error
- Ituran declares USD 0.5 per share Q2 dividend, totaling USD 10 million
- Bitwise’s HYPE ETF clients add $5M despite token 14% slide
- Nexxen names Chance Johnson president in executive reshuffle
- BrainsWay Q2 FY26 adjusted EBITDA more than doubles to USD 3.5 million; revenue rises 35% to USD 17.1 million
- Zion Oil & Gas issues share purchase warrants exercisable at $0.75 under stock purchase plan unit program
- Altimmune Had $519 M in Cash, Cash Equivalents and Investments as of June 30 >ALT
- EuroSports Global 1Q FY27 net loss widens 48.5% to S$ 1.04 million; revenue falls 10% to S$ 7.27 million
- KINETIK HOLDINGS INC. <KNTK.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $59 FROM $53
- PolyPid Q2 FY26 net loss narrows 22% to $7.8 million
- Altimmune Q2 FY26 net loss narrows to $22.8 million; cash and investments climb to $519 million
- AGILENT TECHNOLOGIES, INC. : MORGAN STANLEY RAISES TARGET PRICE TO $175.00 FROM $160.00
- Arbutus Biopharma 2Q Research and Development Expenses $2.9M >ABUS
- Realbotix Q3 FY26 operating loss widens to USD 1.7 million; revenue drops to USD 354,000
- SideChannel FY26 Q3 net loss narrows to $134,000; revenue rises 1.2% to $1.8 million
- Black market threatens major new drug, Eli Lilly (LLY.US) launches global "anti-counterfeiting campaign" for weight-loss medication
- Black markets threaten major new drugs, Eli Lilly (LLY.US) launches global “anti-counterfeit campaign” for weight loss drugs
- COREWEAVE, INC. <CRWV.O>: TRUIST SECURITIES RAISES TARGET PRICE TO $155 FROM $126
- OFF. : MORGAN STANLEY RAISES TARGET PRICE TO $20.00 FROM $19.00
- LUMENTUM HOLDINGS INC <LITE.O>: MORGAN STANLEY RAISES TARGET PRICE TO $1000.00 FROM $900.00
- SUN COMMUNITIES INC <SUI.N>: MORGAN STANLEY CUTS TARGET PRICE TO $126.00 FROM $135.00
- EQUITY LIFESTYLE PROPERTIES, INC. <ELS.N>: MORGAN STANLEY CUTS TARGET PRICE TO $59.00 FROM $62.50
- AMERICAN HOMES 4 RENT : MORGAN STANLEY CUTS TARGET PRICE TO $38.00 FROM $38.50
- MID-AMERICA APARTMENT COMMUNITIES, INC. <MAA.N>: MORGAN STANLEY CUTS TARGET PRICE TO $147.00 FROM $155.00
- UDR, INC. <UDR.N>: MORGAN STANLEY CUTS TARGET PRICE TO $42.00 FROM $44.50
- CAMDEN PROPERTY TRUST <CPT.N>: MORGAN STANLEY CUTS TARGET PRICE TO $118.00 FROM $120.00
- BRIEF-SideChannel Q3 Revenue USD 1.797 Million
- BRIEF-Madison Square Garden Entertainment Q4 Revenue USD 196.3 Million Vs. IBES Estimate USD 166.6 Million
- AECOM : TRUIST SECURITIES CUTS TARGET PRICE TO $85 FROM $102
- Altimmune 2Q Loss/Shr 12c >ALT
- Xilio Therapeutics 2Q Loss $6.37M >XLO
- Arbutus Biopharma 2Q Loss $5.14M >ABUS
- MSG Entertainment 4Q Loss $9.99M >MSGE
- Lexeo Therapeutics releases corporate presentation outlining cardiac gene therapy pipeline, AAVrh.10 platform
- MARINEMAX INC <HZO.N>: TRUIST SECURITIES CUTS TO HOLD FROM BUY; RAISES TARGET PRICE TO $53 FROM $39
- COREWEAVE, INC. <CRWV.O>: BARCLAYS RAISES TARGET PRICE TO $105 FROM $90
- JPMorgan Asset Management raises Cairn Homes stake to 7.81%
- Protalix publishes corporate presentation highlighting Elfabrio commercialization and PRX-115 Phase 2 gout study
- HG Holdings Q2 FY26 operating income before taxes rises 42.7% to $1.35 million; revenue increases 9.7% to $4.46 million
- Solana eyes $80 after bullish RSI divergence and breakout above $75
- Trump’s Iran Warning Raises New Questions for Oil, Markets and 2028 Politics
- SES AI unit UZ Energy becomes Sol-Ark certified battery partner
- Koyo HY26 net profit more than doubled to S$ 1.17 million; revenue rises 77.8% to S$ 58.13 million
- Trimble Board Approves $1 Billion Stock Buyback Plan
- Nordic power contracts edge higher as energy costs and weather factors resonate
- Jeudan H1 FY26 EBIT rises 7% to DKK 569 million; revenue increases 4% to DKK 914 million
- Sound Point Meridian fiscal Q1 net investment income drops to $0.24 a share; net income turns to $0.83 a share
- EXPAND ENERGY CORPORATION <EXE.O>: BENCHMARK CUTS TARGET PRICE TO $109 FROM $124
- Polar Power posts $7.9 million Pacific Islands revenue since 2024 on repeat orders
- SUPER MICRO COMPUTER INC <SMCI.O>: WEDBUSH RAISES TARGET PRICE TO $40 FROM $34
- Matador Resources Chairman, CEO Joseph Foran reports $197,102 common share acquisition
- US Dollar: Inflation data and Middle East risks – Commerzbank
- Electra Battery Materials names Peter Rawlins CFO, effective Aug. 26
- HEMAB THERAPEUTICS HOLDINGS INC <COAG.O>: WEDBUSH RAISES TARGET PRICE TO $64 FROM $55
- VOR BIOPHARMA INC. <VOR.O>: WEDBUSH RAISES TARGET PRICE TO $27 FROM $18
- Yields on Gilts, Eurozone Bonds Fall; Markets Await Updates on Middle East Talks -- Market Talk
- T1 Energy Q2 net loss widens to $36.9 million; net sales rise to $250 million
- Montega lifts Schweizer Electronic to buy, sets EUR 6.5 price target
- ZURA BIO LTD <ZURA.O>: WEDBUSH RAISES TARGET PRICE TO $22 FROM $15
- AMCON Distributing to list on NYSE Texas Exchange on Aug. 13, 2026, maintaining NYSE American primary listing
- First Mining says Springpole Gold Project wins federal environmental approval in Canada
- CAS No-Trade Day: Why F&O Expiry Strategies May Need a Rethink
- Wirtek names Martin Dommerby Kristiansen chairman, replacing Kent Mousten Sorensen
- Cycurion says Nasdaq delisting hearing set for Aug. 20, shares continue trading
- Prime US REIT 1H FY26 net income drops 50.5% to US$3.95 million; revenue slips 0.4% to US$67.06 million
- Unicycive Therapeutics: Unaudited Cash, Cash Equivalents, and Marketable Securities Totaled $61.4M at June 30, With Expected Runway Into 2027 >UNCY
- Unicycive Therapeutics 2Q Loss $1.72M >UNCY
- Unicycive Therapeutics 2Q Loss/Shr 6c >UNCY
- Local Bounti Q2 FY26 net loss narrows 8.15% to 19.82 million; sales rise 14% to 13.85 million
- Ultragreen.ai 1H FY26 NPAT climbs 53% to US$39.2 million; revenue rises 24% to US$87.2 million
- Local Bounti 2Q Loss $19.8M >LOCL
- BRIEF-Local Bounti Q2 Sales USD 13.85 Million
- First Mining Gold Q2 2026 net loss narrows as lower Silver Stream fair-value loss offsets equity-accounted investment loss, company says
- Costamare announces annual shareholder meeting
- Hydro One Q2 2026 profit rises 13% as OEB-approved rate increases lift transmission, distribution revenue
- Could Ethereum could lose top buyer as Bitmine nears 5% target?
- Metro Inc 3Q Sales C$6.97B >MRU.T
- Metro Inc 3Q Net C$211.3M >MRU.T
- Dow Jones Top Markets Headlines at 7 AM ET: U.S. Stock Futures Rise, Lifted By Tech Earnings | Hormuz ...
- Dow Jones Top Company Headlines at 7 AM ET: Bank of America to Deploy $250 Billion to Bolster AI and Energy Infrastructure | Norway ...
- Metro Inc 3Q Adj EPS C$1.24 >MRU.T
- Metro Inc 3Q Pharmacy Same-Store Sales Up 4.8% >MRU.T
- Sutro Biopharma 2Q Rev $9.84M >STRO
- Sutro Biopharma 2Q Loss $38.5M >STRO
- Sutro Biopharma 2Q Loss/Shr $2.33 >STRO
- Oil prices rise after ship attacks, US-Iran talks deadlock
